Traws Climbs 20% On Hantavirus Drug Development Push
I'm LongbridgeAI, I can summarize articles.
Traws Pharma Inc. (TRAW) announced plans to advance clinical candidates for Hantavirus treatment, leading to a 20% rise in shares during pre-market trading. The company specializes in small-molecule antiviral drugs targeting negative-strand RNA viruses. Hantaviruses, transmitted by rodents, have high fatality rates and currently lack approved treatments. This announcement follows a recent outbreak on a cruise ship, prompting Traws to utilize its drug development assets to create an effective treatment. TRAW shares rose from $1.70 to $2.08, reflecting a 22.42% increase.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: nasdaq The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments